Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q1 FY2011 Earnings Presentation
13 slides from Dr. Reddy's Laboratories's earnings presentation, Jul 22, 2010
Slide 1: Q1 FY11 Results Update
Q1 FY11 Results Update Jul 22, 2010
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Consolidated Key Financial Highlights Q1 FY11
Consolidated Key Financial Highlights Q1 FY11 Revenues at Rs. 1,683 crs ; Growth excluding sumatriptan at 4% EBITDA at Rs. 342 crs ; 20% to sales PAT at Rs. 210 crs ; 12% to sales Globally 32 new product launches & 29 product filings 3
Slide 4: P&L Q1 FY11
P&L Q1 FY11 All figures in Rs. Crs. except EPS Q1 FY11 Q1 FY10 Gr% Revenue 1,683 1,819 (7%) Gross Profit 891 1,017 (1%) % to sales 53% 56% SG&A 548 593 (8%) % to sales 33% 33% R&D 99 99 1% % to sales 6% 5% EBITDA 342 436 (22%) % to sales 20% 24% PAT 210 245 (14%) % to sales 12% 13% EPS 12.3 14.4 (
Slide 5: Segmental Analysis: Revenues
Segmental Analysis : Revenues Global Generics FY10 Revenues at Rs. 1,192 crs • Rs. 390 crs • Rs. 278 crs • YoY gr (35%) • YoY gr 16% North India America Russia & Other Europe CIS • Rs. 255 crs • Rs. 194 crs • YoY gr 36% • YoY gr (8%) 5
Slide 6: Global Generics: North America
Global Generics : North America Rs. Crs. Strong recovery in Base Biz post recall issues Sumatriptan in Sep 09 AG 205 $ mn (2%) 11% base biz 21% 5% gr in $ Base business 397 390 77 85 64 Q1 FY10 Q1 FY11 Q3 FY10 Q4 FY10 Q1 FY11 7 ANDA approvals (1 tentative) ; 5 ANDA filings ; 3 new product la
Slide 7: Global Generics: Russia
Global Generics : Russia Pharmexpert (MAT Mar 10) Rs. Crs. 35% Secondary Sales Growth : 206 Dr. Reddy’s 33% 153 Industry 21% Dr. Reddy’s Rank 15th Q1 FY10 Q1 FY11 YoY growth of 44% and sequential growth of 32% in dollar terms ; Growth driven by volume increase largely in key brands o
Slide 8: Global Generics: India
Global Generics : India ORG IMS (MAT Jun 10) Rs. Crs. 16% Secondary Sales Growth : Dr. Reddy’s 22% 278 Industry 20% 239 Top 10 21% Dr. Reddy’s Rank 14th Q1 FY10 Q1 FY11 Growth largely driven by new product launches and increased volumes in existing business New product launches
Slide 9: Global Generics: Europe
Global Generics : Europe Germany Rest of Europe Rs. Crs. (18%) 161 29% 132 52 40 Q1 FY10 Q1 FY11 Q1 FY10 Q1 FY11 Germany Revenues of Euro 23 mn ; marginal decline of 6% in local currency terms Competitiveness in bidding for new tenders to be leveraged by : Benefit of significant optimization o
Slide 10: Pharmaceutical Services & Active Ingredients
Pharmaceutical Services & Active Ingredients DMFs Pipeline : Rs. Crs. (8%) Cumulative 378 US 156 487 450 Europe 90 Canada 59 Q1 FY10 Q1 FY11 RoW 73 Revenue growth is flat in constant currency terms No new significant launches of API in the recent quarters and the impact of volume incre
Slide 11: Other Updates
Other Updates District Court of New Jersey granted a preliminary injunction to Sanofi- Aventis blocking our proposed launch of the generic version of Allegra D24 GSK Alliance : Shipped products to Mexico, Brazil & Maldova in this quarter Cumulatively filed > 70 dossiers in various emerging m
Slide 12: Q&A Session
Q&A Session July 22, 2010 LIFE , RESEARCH «. HOPE
Slide 13: Key Balance Sheet Items
Key Balance Sheet Items Rs. Crs. Jun 10 Mar 10 Cash & Cash Equivalents 637 658 Trade receivables 1,277 1,196 Inventories 1,445 1,337 Property, plant & equipment 2,394 2,246 Loans & borrowings (current & non current) 1,387 1,470 Trade payables 969 932 • Capex for the quarter is at Rs. 187 crores • De
Dr. Reddy's Laboratories — Q1 FY2011 Earnings Presentation on 6ix